Present and Future in the Treatment of Diabetic Kidney Disease
Arriba, Gabriel de
MetadataShow full item record
Diabetic kidney disease is the leading cause of end-stage renal disease. Albuminuria is recognized as the most important prognostic factor for chronic kidney disease progression. For this reason, blockade of renin-angiotensin system remains the main recommended strategy, with either angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. However, other antiproteinuric treatments have begun to be studied, such as direct renin inhibitors or aldosterone blockers. Beyond antiproteinuric treatments, other drugs such as pentoxifylline or bardoxolone have yielded conflicting results. Finally, alternative pathogenic pathways are being explored, and emerging therapies including antifibrotic agents, endothelin receptor antagonists, or transcription factors show promising results. The aim of this review is to explain the advances in newer agents to treat diabetic kidney disease, along with the background of the renin-angiotensin system blockade.
Is part ofJournal of Diabetes Research, 2015, vol. 2015, ID. 801348
European research projects
The following license files are associated with this item:
Showing items related by title, author, creator and subject.
Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease Anguiano, Lidia; Riera, Marta; Pascual, Julio; Valdivielso Revilla, José Manuel; Barrios, Clara; Betriu i Bars, M. Àngels; Mojal, Sergi; Fernández i Giráldez, Elvira; Soler, María José (Oxford University Press, 2015)
Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. Arcidiacono, Maria V.; Rimondi, Erika; Maietti, Elisa; Melloni, Elisabetta; Tisato, Veronica; Gallo, Stefania; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira; Betriu i Bars, M. Àngels; Voltan, Rebecca; Zauli, Giorgio; Volpato, Stefano; Secchiero, Paola (Public Library of Science, 2018-09-11)Background: Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. ...
Carmona, Andrés; Agüera, Maria L.; Luna-Ruiz, Carlos; Buendía, Paula; Calleros-Basilio, Laura; García-Jerez, Andrea; Rodríguez-Puyol, Manuel; Arias, Manuel; Arias-Guillen, Marta; Arriba, Gabriel de; Ballarin, José; Bernis, Carmen; Fernández i Giráldez, Elvira; García-Rebollo, Sagrario; Mancha, Javier; Peso, Gloria del; Pérez, Estefanía; Poch, Esteban; Portolés, José M.; Rodríguez-Puyol, Diego; Sánchez-Villanueva, Rafael; Sarró, Felipe; Torres, Armando; Martín-Malo, Alejandro; Aljama, Pedro; Ramírez, Rafael; Carracedo, Júlia (American Physiological Society, 2017-04-01)Patients with Stage 5 chronic kidney disease who are on hemodialysis (HD) remain in a chronic inflammatory state, characterized by the accumulation of uremic toxins that induce endothelial damage and cardiovascular disease ...